Floatz logo

TTI-621

Squamous Cell Carcinoma

PfizerPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

29 Active assets in the Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Neonc Technologies, Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Oxford
Phase 3BB
Docetaxel
Hummingbird Bioscience
Phase 2BB
Eloxatin
University of Oxford
Phase 3BB
Fibrin Sealant
Oxford University Hospitals NHS Trust
Phase 4BB

View all 50 →

Same molecule, other indications

TTI-621 is also rated in:

Human Papillomavirus-Related Malignant NeoplasmDormant
CC
Indicative ·
43 / 100
View asset →
cutaneous neuroendocrine carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
mycosis fungoidesDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →